Agoracom Blog

The Roundup – @Novamind_Inc $ $NVMDF $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 9:48 AM on Saturday, March 20th, 2021

A weekly summary of Novamind news and media

FEATURES March 19, 2021

Why Merck chose Novamind for a new clinical trial

Our deep experience hosting clinical trials and treating depression drew Merck to test a new drug aimed at treatment-resistant depression.

FEATURES March 15, 2021

Yaron Conforti on democratizing access to psychedelic medicine

CEO and Director Yaron Conforti talks with Paul Austin, founder of Third Wave, about how Novamind provides safe, legal access to psychedelic medicine today. 

View all media

Novamind Partners with Merck for New Treatment-Resistant Depression Trial

March 18, 2021

View all press releases

Follow @novamind_inc on Instagram

This image has an empty alt attribute; its file name is NM_300x300.jpg

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Tags: , , , , , , ,

Comments are closed.